Earnings 12 Mar: Sensorion SA (ALSEN.PA EURONEXT) pre-market 09 Mar 2026: outlook

Sensorion SA (ALSEN.PA) trades pre-market at €0.40, down -5.62%, ahead of its earnings announcement on 12 Mar 2026. The ALSEN.PA stock has seen heavier volume today at 3,275,857 shares versus a 50-day average of 1,967,102, suggesting traders are positioning into results. We outline the key catalysts, near-term risks, and what margins and cash metrics mean for guidance and the post-release move.

ALSEN.PA stock: pre-market price, volume and technicals

Sensorion is quoted on EURONEXT in Europe at €0.40 pre-market with a one-day move of -5.62%. Trading shows relative volume 1.68x, day range €0.40–€0.44, and average 50/200-day prices at €0.33 and €0.34 respectively.

Short-term indicators show momentum but elevated volatility. RSI sits near 61.83, ADX at 35.28 signals a strong trend, and Bollinger upper band is €0.41. These technicals mean the market is reactive into earnings.

ALSEN.PA stock: fundamentals and key ratios

Sensorion is a clinical-stage biotechnology firm with a market cap near €121.04M and 300,336,842 shares outstanding. Latest reported EPS is -0.09, PE reads -4.48, and PB is 2.13.

Cash per share is €0.19 and current ratio is 4.90, showing liquidity buffer ahead of clinical milestones. Price-to-sales is elevated at 20.71, reflecting low revenue and high R&D weighting.

ALSEN.PA stock: earnings catalysts and calendar

The company lists an earnings announcement on 12 Mar 2026, which is the central catalyst for near-term moves. Investors will focus on cash runway commentary, R&D spending, and any clinical updates on OTOF-GT and USHER-T1-GT.

Market sensitivity is high because Sensorion is clinical-stage and guidance or enrollment updates can change the valuation quickly. See the Reuters company page for latest filings and news Reuters.

Meyka AI rates ALSEN.PA with a score out of 100: grade and valuation view

Meyka AI rates ALSEN.PA with a score out of 100: 66.36/100 — Grade: B — Suggestion: HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus.

Valuation signals show mixed signals. Enterprise value over sales is 12.99 and free cash flow yields are negative. These metrics weigh on upside absent positive clinical news. These grades are not guaranteed and we are not financial advisors.

ALSEN.PA stock: forecasts, price targets and scenario planning

Meyka AI’s forecast model projects a monthly level of €0.27 and a yearly projection of €0.14 for ALSEN.PA stock. Compared with the current price of €0.403, the monthly projection implies a -32.98% move and the yearly projection implies -64.06%. Forecasts are model-based projections and not guarantees.

Scenario price targets: bull case €0.60 (near year high €0.60, implied upside +48.89% vs €0.403), base case €0.40, bear case €0.15 (near year low €0.15, implied downside -62.78%). Use targets as guideposts, not certainties.

ALSEN.PA stock: risks, sector context and what to watch

Key risks include trial setbacks, cash burn, and regulatory delays typical for biotechnology names. Sensorion’s research-to-revenue profile drives higher multiples and binary outcomes.

Healthcare sector peers trade at higher average P/E and PB ratios. Relative to the European Healthcare sector, Sensorion carries more volatility and less revenue, so clinical readouts and cash guidance will drive post-earnings moves. For broader market context consult Investing.com for comparable sector flows Investing.com.

Final Thoughts

Key takeaways: ALSEN.PA stock trades pre-market at €0.40 with elevated volume and a clear earnings catalyst on 12 Mar 2026. Fundamentals show a cash buffer (€0.19 per share) and a strong current ratio (4.90), but negative EPS (-0.09) and stretched price-to-sales (20.71) reflect clinical-stage valuation. Meyka AI’s forecast model projects €0.27 monthly and €0.14 yearly, implying downside of -32.98% and -64.06% from the current €0.403 price. Our scenario targets are a bull case €0.60, base €0.40, and bear €0.15, with implied moves from €0.403 of +48.89% and -62.78% respectively. Traders should weigh binary clinical risk, cash runway commentary, and guidance clarity. Use the earnings release and Q&A to reprice exposure, and consult our Meyka AI-powered market analysis tools for real-time updates. Forecasts are model-based projections and not guarantees.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.